ReviewOncology letters2026
Astragalin: A promising herbal compound with broad anticancer potential (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The flavonoid astragalin induces apoptosis in lung adenocarcinoma and correlates with a prognostic cell cycle gene signature associated with PANoptosis.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, compounds that are active ingredients in herbal medicines have been investigated for their ability to treat cancer. Astragalin may exert anticancer effects through anti-inflammatory, anti-glycosylation, anti-adipogenesis, antioxidant and neuroprotective effects; however, there has been no literature review on the specific mechanism of action of astragalin in cancer, to the best of our knowledge. Therefore, the present review searched and reviewed the literature related to astragalin and cancer, and summarized the possible mechanisms. The results revealed that astragalin affects the proliferation, invasion and angiogenesis of cancer cells through participating in signaling pathways, regulating apoptotic proteins, inactivating oncogenes and suppressor genes, as well as the tumor microenvironment, angiogenesis and other mechanisms of action. In turn, this exerts antitumor effects and reverses chemotherapy resistance. Astragalin is expected to serve a greater role in the prevention and treatment of malignant tumors in the future due to its availability, safety and economy, thus providing new hope for global cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.